FDA testing benefit/risk framework

Share this article:

The FDA says it is developing a qualitative framework for benefit/risk analysis out of recent case studies that suggested five key considerations a regulator must think about — severity of condition, unmet medical need, clinical benefit, risk and risk management.

The project was described by drug operations research analyst Patrick Frey for a Regulatory Affairs Professionals Society annual meeting session in September.

He said it was conceptualized last year and has since been piloted with four retrospective reviews or case studies where the agency was faced with difficult decisions in benefit/risk assessments.

The framework is designed to capture “key factors” on the reviewer's mind when a benefit/risk assessment is made.  It can be broadly applicable as a template and also includes a methodology for communicating the results to external and internal audiences.

“The framework is intended to provide structure to internal deliberations by helping to extract explicit information related to the key considerations,” Frey said. “And it can function as a living document, which is easily updated as new information becomes available.”

For the next six months, Frey said the FDA's drugs center plans to continue to keep road testing the framework with additional retrospective cases.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?